EUVIMEDEUVIMED entdecken
Open Access

The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors

Andrew T Jones iD, Alessandra E Marino iD, Tetyana Martynyuk, Stylianos Bournazos iD, Jeffrey V Ravetch iD

Science · 06.11.2025 · 390 (6773)

DOI: 10.1126/science.adv2927 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 06.11.2025. Verfasst von Andrew T Jones und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA. Hauptthemen laut MEDLINE: Receptors, IgG, Immunoglobulin G, Lectins, C-Type, Cell Adhesion Molecules. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intravenous immunoglobulin (IVIG) administered at high doses is used to treat a wide array of autoimmune diseases. Studies in murine models have identified that the anti-inflammatory activity of IVIG is dependent on sialylation of the N-linked glycan on the CH2 domain of immunoglobulin G (IgG), the type I IgG inhibitory Fc receptor FcγRIIB, and the type II Fc receptor dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN). We hypothesized that DC-SIGN, a C-type lectin, may directly interact with glycans on FcγRIIB, augmenting its ability to bind sialylated IgG. We found that Fc-engineering sialylated IgG1 to enhance its affinity for FcγRIIB resulted in a molecule that was more potent than IVIG in reducing the inflammatory sequelae of antibody or T cell–mediated autoimmune diseases, providing the basis for a class of potent anti-inflammatory therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, IgGImmunoglobulin GLectins, C-TypeCell Adhesion MoleculesImmunoglobulins, IntravenousAnti-Inflammatory AgentsReceptors, Cell SurfaceAnimalsMiceHumansImmunoglobulin Fc FragmentsAutoimmune DiseasesN-Acetylneuraminic AcidProtein EngineeringPolysaccharidesMice, Inbred C57BLDC-Specific ICAM-3 Grabbing Nonintegrin

Substanzen

Receptors, IgGImmunoglobulin GLectins, C-TypeCell Adhesion MoleculesImmunoglobulins, IntravenousAnti-Inflammatory AgentsReceptors, Cell SurfaceImmunoglobulin Fc FragmentsN-Acetylneuraminic AcidPolysaccharides

Autor:innen und Institutionen

  • Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA.

ORCID-Profile: Andrew T Jones, Alessandra E Marino, Stylianos Bournazos, Jeffrey V Ravetch

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Jones, A. T., Marino, A. E., Martynyuk, T., Bournazos, S., & Ravetch, J. V. (2025). The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors. Science, 390(6773). https://doi.org/10.1126/science.adv2927

Vancouver

Jones AT, Marino AE, Martynyuk T, Bournazos S, Ravetch JV. The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors. Science. 2025;390(6773). doi:10.1126/science.adv2927

BibTeX
@article{Jones2025,
  author = {Jones, Andrew T and Marino, Alessandra E and Martynyuk, Tetyana and Bournazos, Stylianos and Ravetch, Jeffrey V},
  title = {The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors},
  journal = {Science},
  year = {2025},
  volume = {390},
  number = {6773},
  doi = {10.1126/science.adv2927}
}
Kostenlos starten →